New combo therapy shows promise for tough bladder cancer cases
NCT ID NCT04610671
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This early-stage study tested a combination of two drugs—CG0070 (a virus that targets cancer cells) and nivolumab (an immunotherapy that boosts the immune system)—in 21 people with muscle-invasive bladder cancer who were not eligible for standard chemotherapy. The goal was to see if the combination was safe and could help shrink tumors before surgery. The trial has been completed, but results are not yet widely available.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
CG0070 (a virus-based therapy) and nivolumab (an immunotherapy drug)
What this could lead to
If successful, this combination could offer a new treatment option for bladder cancer patients who cannot take standard chemotherapy.
What could go wrong
This is a very early (Phase 1) and small study (21 people), so results may not apply to everyone. Side effects from the drugs could be serious.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BLADDER CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Moffitt Cancer Center
Tampa, Florida, 33612, United States